Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Doreen, Luedtke"'
Autor:
Sascha Keller, Ulrich Kunz, Ulrike Schmid, Jack Beusmans, Martin Büchert, Min He, Girish Jayadeva, Christophe Le Tourneau, Doreen Luedtke, Heiko G. Niessen, Zohra Oum’hamed, Sina Pleiner, Xiaoning Wang, Ralph Graeser
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-18 (2024)
Abstract Background BI 836880 is a humanized bispecific nanobody® that binds to and blocks vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2). A comprehensive biomarker and modeling approach is presented here that supported dose fi
Externí odkaz:
https://doaj.org/article/e16d3e8186014e00ab772fd03b57d4cc
Autor:
Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz, Armin Schultz
Publikováno v:
ERJ Open Research, Vol 8, Iss 4 (2022)
Introduction BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. Phase I and Ic studies were conducted to investigate the safety, tolerability and pharmacokinetics of BI 1015550 in healthy male subjects and patients
Externí odkaz:
https://doaj.org/article/21b9b0816508498c90339a882a036afe
Autor:
Toby M, Maher, Christina, Schlecker, Doreen, Luedtke, Sebastian, Bossert, Donald F, Zoz, Armin, Schultz
IntroductionBI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. Phase I and Ic studies were conducted to investigate the safety, tolerability and pharmacokinetics of BI 1015550 in healthy male subjects and patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cc33ee0552be7587e3a47357d3f4ec9
http://hdl.handle.net/10044/1/100466
http://hdl.handle.net/10044/1/100466
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 43:533-541
Nintedanib is a substrate for p-glycoprotein which can impact bioavailability. We investigated the effects of ketoconazole, a p-glycoprotein inhibitor, and rifampicin, a p-glycoprotein inducer, on the pharmacokinetics of nintedanib. In the ketoconazo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb662ae3edfbe2560f0f3e74f8352d4
https://doi.org/10.1007/s13318-018-0467-9
https://doi.org/10.1007/s13318-018-0467-9
Autor:
David Schnell, Raimund Kuelzer, Gunther Kretschmar, Claudia Dallinger, Ulrike Schmid, Kristell Marzin, Doreen Luedtke, Rozsa Schlenker-Herceg, Sandrine Kraemer
Publikováno v:
Journal of Clinical Pharmacology
Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non–small cell lung cancer and idiopathic pulmonary fibrosis (IPF). This phase 1 open‐label study investigated the influence of mild and moderate hepatic impair
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ab38af1d971cc804850588f708ae44e
https://pubmed.ncbi.nlm.nih.gov/29106740
https://pubmed.ncbi.nlm.nih.gov/29106740
Autor:
Anna Unseld, Doreen Luedtke, Stephan Formella, Martina Wein, Atef Halabi, Alan Hamilton, Christina Kunz
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Christina Kunz,1 Doreen Luedtke,1 Anna Unseld,2 Alan Hamilton,3 Atef Halabi,4 Martina Wein,5 Stephan Formella6 1Translational Medicine and Clinical Pharmacology, 2Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH and Co KG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99b58fb6fd921f74705dcaaf70fb9a9c
https://www.dovepress.com/pharmacokinetics-and-safety-of-olodaterol-administered-with-the-respim-peer-reviewed-article-COPD
https://www.dovepress.com/pharmacokinetics-and-safety-of-olodaterol-administered-with-the-respim-peer-reviewed-article-COPD